2018/01/24

European Research Training Network to decipher the ubiquitin code

As of 1st of January, the ITN project UbiCODE has started ! The network is coordinated by Dr Manuel S. Rodríguez (ITAV-CNRS) and co-coordinated by Dr Rosa Barrio at CIC bioGUNE. The UPV/EHU (Leioa) collaborates as Associated Partner in the project.

The key scientific mission of the programme is to understand how protein modification with Ub/Ubls is generated (written), regulated (edited), recognised (read) and connected with effector functions (interpreted) to regulate cellular plasticity.

Each beneficiary institution will host an Early Stage Researcher for 36 months to decipher the ubiquitin code. Students will acquire scientific skills in experimental biomedical sciences in the field of Ubiquitin from expert laboratories at the fore-front of the field, in a highly stimulating and collaborative environment.

Follow the project on Facebook and Twitter for regular updates and original content.

Link to our website : http://ubicode.eu/
Link to our Facebook: https://www.facebook.com/UbicodeITN/
Link to our Twitter: https://twitter.com/UBI_CODE
Link to our Instagram: https://www.instagram.com/ubicode/

Beneficiaries

• CNRS-ITAV – FR – Manuel Rodriguez (coordinator)
• CIC bioGUNE – ES - Rosa BARRIO (co-coordinator)
• CNRS-CRBM – FR - Dimitris XIRODIMAS
• University of Liverpool – UK - Sylvie URBE
• IMB – DE - Helle ULRICH
• LUMC-MCB – NL – Alfred VERTEGAAL
• MPG-MPI-IE – DE - Andrea PICHLER
• LUMC – NL - Huib OVAA
• FMI – CH - Nicolas THOMA
• MRC-Cambridge – UK - David KOMANDER
• GUF – DE - Ivan DIKIC
• University of Dundee – UK - Ronald HAY
• Novo Nordisk – DK - Thomas E. NIELSEN

Associated Partners

• University of the Basque Country UPV/EHU – ES - Ugo MAYOR
• Nova Medical School NOVA – PT - Rune MATTHIESEN
• Hybrigenics Hybrigenics – FR -Jean-Christophe RAIN
• Novartis Novartis - CH - Martin RENATUS
• UbiQ UbiQ - NL – Farid EL OUALID
• Yellow Research B.V. - NL - Lotte JASPERS
• The Naked Scientists Ltd - UK - Chris SMITH
• Ubiquigent Ltd - UK - Jason BROWN
• Merck - DE - Teresa DOLT

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765445.